Diclegis is a delayed-release tablet intended for women who have not adequately responded to conservative management of nausea and vomiting during pregnancy, such as dietary and lifestyle modifications. These modifications include eating several small meals instead of three large meals, eating bland foods that are low in fat and easy to digest and avoiding smells that can trigger nausea.
Diclegis was studied in 261 women experiencing nausea and vomiting due to pregnancy. Study participants in the clinical trial were at least 18 years old and had been pregnant for at least 7 weeks and up to 14 weeks. Women were randomly assigned to receive two weeks of treatment with Diclegis or a placebo. The study results showed that women taking Diclegis experienced greater improvement in nausea and vomiting than those taking placebo. Additionally, observational (epidemiological) studies have shown that the combination of active ingredients in Diclegis does not pose an increased risk of harm to the fetus.
The body’s own “training manual” for attacking HIV has been recorded by US scientists and it is hoped it can be used to design vaccines.
HIV mutates in order to survive the onslaught of a patient’s immune system.
Eye drops designed to lower cholesterol may be able to prevent one of the most common forms of blindness, according to US researchers.
They showed how high cholesterol levels could affect the immune system and lead to macular degeneration.
FDA has approved canagliflozin (Invokana) tablets, the first diabetes treatment in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used with diet and exercise, canagliflozin improves glycemic control in adults with type 2 diabetes.
Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels in diabetics who have elevated levels. Its safety and effectiveness were evaluated in nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed improvement in hemoglobin A1c levels (a measure of blood sugar control) and fasting plasma glucose (blood sugar) levels.
According to a new Consumer Reports investigative study published Thursday, there is rampant variation in the price of generic drugs as large U.S. pharmacy chains — including CVS, Rite Aid, and Target — marking up the prices of generic drug versions for common medications by as much as 18 times what wholesale chains like Costco charge. That price variance ends up costing Americans, who spend an average of $758 out-of-pocket on drugs every year, hundreds of dollars in unnecessary spending each month.
In California, a package of bills intended to allow pharmacists (SB 493), nurse practitioners (SB 491), and optometrists (SB 492) to practice to the full extent of their education and training was introduced on February 21 and announced at a news conference on March 13by state Sen. Ed Hernandez, OD, (D-24) who is Chair of the Senate Health Committee. A parallel bill introduced for physician assistants is being carried by another author.
The California Pharmacists Association (CPhA)supports the proposed legislation, which is authored by Hernandez, a practicing optometrist, according to CPhA CEO Jon R. Roth, CAE. The bills are just now beginning their journey through the legislative process.
The U.S. Supreme Court hears arguments Monday in a case worth billions of dollars to pharmaceutical companies and American consumers. The issue is whether brand-name drug manufacturers may pay generic drug manufacturers to keep generics off the market. These payments — a form of settlement in patent litigation — began to blossom about a decade ago when the courts, for the first time, appeared to bless them.
Consumer advocates, health care organizations and retail outlets call these payments “pay to delay.” The drugmakers hate that term and have a different name. They call the payments “reverse settlements.”
The injuries that Karen Bartlett suffered after taking a mild pain pill are enough to make anyone squeamish.
Ms. Bartlett, who lives in Plaistow, N.H., developed a rare but severe reaction to the anti-inflammatory drug sulindac after a doctor prescribed it to treat shoulder pain in 2004. Within weeks of taking the drug, her skin began to slough off until nearly two-thirds of it was gone.
She spent almost two months in a burn unit, and months more in a medically induced coma. The reaction permanently damaged her lungs and esophagus and rendered her legally blind.